Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Completes Bioenvision Takeover

This article was originally published in The Pink Sheet Daily

Executive Summary

Extended stockholder vote supports merger, with 67 percent of shares voted in favor of $345 million deal.

You may also be interested in...



Genzyme: Next-Generation Sevelamer Bound For Clinic Next Year

Enzyme-replacement sales strong as firm builds on renal franchise.

Genzyme: Next-Generation Sevelamer Bound For Clinic Next Year

Enzyme-replacement sales strong as firm builds on renal franchise.

Genzyme Aims To File Clolar Label Expansion For Acute Myelogenous Leukemia In Mid-2008

The firm projects global sales of clofarabine for blood cancers to peak at $600 million over ten years, CEO Termeer says.

Topics

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel